Revenio Group Oyj - Changes in company's own shares

Revenio Group Corporation: Transfer of the Company's own shares

Revenio Group Corporation, Stock Exchange Release, June 21, 2017 at 16:30

Transfer of the Company's own shares

Revenio Group Corporation has transferred on June 21, 2017 1,500 shares (REG1V)
to the members of the Board of Directors as part of remuneration of the Board.

Revenio Group Corporation's AGM decided on March 22, 2017 that 40% of the fee
paid to a board member should be paid in company shares while 60 per cent will
comprise a monetary payment. The AGM decided that the Chair of the Board be
entitled to an annual emolument of EUR 48,000 and the other Board members to an
annual emolument of EUR 24,000.

As a result of these transfers, the share-based board member fees have been
completely settled for the year 2017. Revenio Group Corporation now holds a
total of 3,459 of its own shares.

Revenio Group Corporation
Timo Hildén
President and CEO

For additional information:
President & CEO Timo Hildén, gsm +358 40 580 4774
timo.hilden@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53.5% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2016, Revenio Group's net sales totaled MEUR 23.4, with its operating profit
for continuing operations standing at 30.1%. Revenio Group Corporation is listed
on Nasdaq Helsinki.



[]